STAAR Surgical stock
STAANASDAQSTAAR Surgical Company, HealthcareISIN US8523123052
45Score 45 out of 100, Weak
Price and trend
71 / 100
Price history
+3.6% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 12% above it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 20% below its 52-week high. Largest decline in 20 years: 91% (September 2021 to April 2025).
Chart figures for advanced users
- SMA 50$22.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$23.86
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.10
- The lowest closing price of the last twelve months.
- Resistance$33.34
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- STAAR Surgical Company belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $1.34B, is number 38 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $239.44M (down 23.7% year on year) and a loss of $80.45M.
- For fiscal 2026, analysts expect on average revenue of $336.96M (up 40.7%) and adjusted earnings per share of $0.31.
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 471 of 714 in Healthcare, median 53.
- Our model puts fair value at $10.27, with the price 160% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.
- More cash than debtCash $206.41M, financial debt $33.64M.Stability 70
- Analysts expect strong earnings growthUp 26.3% a year through 2029 (estimates from 8 analysts).
Weaknesses
- Margin fallingOperating margin −19.2%, average of the prior years 8.7% (to 2024).Profitability 33
- Above fair valuePrice 160% above the fair value of $10.27.Valuation 14
- Turned to a lossEarnings per share from $0.13 in 2020 to −$1.62.Growth 45
Its standout strengths are technical analysis and stability, while capital allocation and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 43 to 45.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $7.34 and expensive above $17.12 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $8.30, at 7.8% it would be $13.25.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 2 Oct 2026, revenue rose 42.4% on the twelve months before. Up to 2022 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 11.7% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 76%, operating −19%, net −34%. Last 12 months: net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 2 Mar 2027in 110 days
- Last reported
- 4 Nov 2026EPS reported $0.11 (expected $0.05)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 8.1% since 15 Oct 2026.
- Earnings per share
- $0.31+8.1%
- Revenue
- $336.96M+0.8%
- Earnings per share
- $0.55+0.6%
- Revenue
- $365.9M+0.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +1.6%No formal guidance: third quarter revenue moderately lower than the second quarter because of seasonality, cash well over $200 million expected at the end of 2026.
“The company currently expects to generate significant free cash flow in the second half of the year, ending 2026 with well over $200 million in cash.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Broadwood Partners, L.p.Purchase
13 Mar 2026, Board
- Shares
- 316,017
- Price
- $18.62
- Value
- $5.88M
- Broadwood Partners, L.p.Purchase
12 Mar 2026, Board
- Shares
- 299,432
- Price
- $18.12
- Value
- $5.42M
- Broadwood Partners, L.p.Purchase
11 Mar 2026, Board
- Shares
- 54,764
- Price
- $17.52
- Value
- $959,558
Show 5 more
- Broadwood Partners, L.p.Purchase
9 Jan 2026, Major holder
- Shares
- 27,485
- Price
- $22.05
- Value
- $606,138
- Broadwood Partners, L.p.Purchase
8 Jan 2026, Major holder
- Shares
- 3,240
- Price
- $21.94
- Value
- $71,082
- Broadwood Partners, L.p.Purchase
7 Jan 2026, Major holder
- Shares
- 66,467
- Price
- $22.00
- Value
- $1.46M
- Broadwood Partners, L.p.Purchase
6 Jan 2026, Major holder
- Shares
- 336,946
- Price
- $21.62
- Value
- $7.28M
- Broadwood Partners, L.p.Purchase
21 Nov 2025, Major holder
- Shares
- 797,486
- Price
- $27.86
- Value
- $22.22M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at STAAR Surgical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- DENTSPLY SIRONAXRAY $1.95B48
- Kestra Medical TechnologiesKMTS $1.88B45
- SKAN GroupSKAN.SW $1.88B72
- LeMaitre VascularLMAT $1.81B70
- GerresheimerGXI.DE $1.23B48
- Safilo GroupSFL.MI $952.24M61
- Dynavox GroupDYVOX.ST $784.94M66
- AngioDynamicsANGO $522.32M40
ETFs that hold STAAR Surgical
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.08% | 0.40% | €807M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.04% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.35% | €434.1M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 2 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 21 Feb 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.